Certain Strontium-Rubidium Radioisotope Infusion Systems, and Components Thereof Including Generators; Institution of Investigation, 19112-19113 [2018-09068]
Download as PDF
<![CDATA[
amozie on DSK30RV082PROD with NOTICES
19112
Federal Register / Vol. 83, No. 84 / Tuesday, May 1, 2018 / Notices
(a) Production (quantity) and, if
known, an estimate of the percentage of
total production of Subject Merchandise
in the Subject Country accounted for by
your firm’s(s’) production;
(b) Capacity (quantity) of your firm(s)
to produce the Subject Merchandise in
the Subject Country (that is, the level of
production that your establishment(s)
could reasonably have expected to
attain during the year, assuming normal
operating conditions (using equipment
and machinery in place and ready to
operate), normal operating levels (hours
per week/weeks per year), time for
downtime, maintenance, repair, and
cleanup, and a typical or representative
product mix); and
(c) the quantity and value of your
firm’s(s’) exports to the United States of
Subject Merchandise and, if known, an
estimate of the percentage of total
exports to the United States of Subject
Merchandise from the Subject Country
accounted for by your firm’s(s’) exports.
(12) Identify significant changes, if
any, in the supply and demand
conditions or business cycle for the
Domestic Like Product that have
occurred in the United States or in the
market for the Subject Merchandise in
the Subject Country after 2012, and
significant changes, if any, that are
likely to occur within a reasonably
foreseeable time. Supply conditions to
consider include technology;
production methods; development
efforts; ability to increase production
(including the shift of production
facilities used for other products and the
use, cost, or availability of major inputs
into production); and factors related to
the ability to shift supply among
different national markets (including
barriers to importation in foreign
markets or changes in market demand
abroad). Demand conditions to consider
include end uses and applications; the
existence and availability of substitute
products; and the level of competition
among the Domestic Like Product
produced in the United States, Subject
Merchandise produced in the Subject
Country, and such merchandise from
other countries.
(13) (OPTIONAL) A statement of
whether you agree with the above
definitions of the Domestic Like Product
and Domestic Industry; if you disagree
with either or both of these definitions,
please explain why and provide
alternative definitions.
Authority: This proceeding is being
conducted under authority of title VII of the
Tariff Act of 1930; this notice is published
pursuant to section 207.61 of the
Commission’s rules.
By order of the Commission.
VerDate Sep<11>2014
18:12 Apr 30, 2018
Jkt 244001
Issued: April 23, 2018.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2018–08793 Filed 4–30–18; 8:45 am]
BILLING CODE 7020–02–P
INTERNATIONAL TRADE
COMMISSION
[Investigation No. 337–TA–1110]
Certain Strontium-Rubidium
Radioisotope Infusion Systems, and
Components Thereof Including
Generators; Institution of Investigation
U.S. International Trade
Commission
ACTION: Notice.
AGENCY:
Notice is hereby given that a
complaint was filed with the U.S.
International Trade Commission on
March 27, 2018, under section 337 of
the Tariff Act of 1930, as amended, on
behalf of Bracco Diagnostics Inc. of
Monroe Township, New Jersey. An
amended complaint was filed on April
13, 2018. The amended complaint
alleges violations of section 337 based
upon the importation into the United
States, the sale for importation, and the
sale within the United States after
importation of certain strontiumrubidium radioisotope infusion systems,
and components thereof including
generators by reason of infringement of
U.S. Patent No. 9,814,826 (‘‘the ’826
patent’’); U.S. Patent No. 9,750,869 (‘‘the
’869 patent’’); and U.S. Patent No.
9,750,870 (‘‘the ’870 patent’’). The
amended complaint further alleges that
an industry in the United States exists
as required by the applicable Federal
Statute.
The complainant requests that the
Commission institute an investigation
and, after the investigation, issue a
limited exclusion order and cease and
desist orders.
ADDRESSES: The complaint, except for
any confidential information contained
therein, is available for inspection
during official business hours (8:45 a.m.
to 5:15 p.m.) in the Office of the
Secretary, U.S. International Trade
Commission, 500 E Street SW, Room
112, Washington, DC 20436, telephone
(202) 205–2000. Hearing impaired
individuals are advised that information
on this matter can be obtained by
contacting the Commission’s TDD
terminal on (202) 205–1810. Persons
with mobility impairments who will
need special assistance in gaining access
to the Commission should contact the
Office of the Secretary at (202) 205–
2000. General information concerning
SUMMARY:
PO 00000
Frm 00074
Fmt 4703
Sfmt 4703
the Commission may also be obtained
by accessing its internet server at
https://www.usitc.gov. The public
record for this investigation may be
viewed on the Commission’s electronic
docket (EDIS) at https://edis.usitc.gov.
FOR FURTHER INFORMATION CONTACT:
Pathenia M. Proctor, The Office of
Unfair Import Investigations, U.S.
International Trade Commission,
telephone (202) 205–2560.
SUPPLEMENTARY INFORMATION:
Authority: The authority for institution of
this investigation is contained in section 337
of the Tariff Act of 1930, as amended, 19
U.S.C. 1337 and in section 210.10 of the
Commission’s Rules of Practice and
Procedure, 19 CFR 210.10 (2018).
Scope of Investigation: Having
considered the complaint, the U.S.
International Trade Commission, on
April 24, 2018, ordered that—
(1) Pursuant to subsection (b) of
section 337 of the Tariff Act of 1930, as
amended, an investigation be instituted
to determine whether there is a
violation of subsection (a)(1)(B) of
section 337 in the importation into the
United States, the sale for importation,
or the sale within the United States after
importation of certain strontiumrubidium radioisotope infusion systems,
and components thereof including
generators by reason of infringement of
one or more of claims 1–3, 5, 9–14, 17–
19, 26, and 28 of the ’826 patent; claims
1–5, 8, 14, 24, and 27–30 of the ’869
patent; and claims 1, 2, 8–13, 16, 17, 22,
and 27 of the ’870 patent; and whether
an industry in the United States exists,
or is in the process of being established,
as required by subsection (a)(2) of
section 337;
(2) Pursuant to Commission Rule
210.50(b)(1), 19 CFR 210.50(b)(1), the
presiding administrative law judge shall
take evidence or other information and
hear arguments from the parties and
other interested persons with respect to
the public interest in this investigation,
as appropriate, and provide the
Commission with findings of fact and a
recommended determination on this
issue, which shall be limited to the
statutory public interest factors set forth
in 19 U.S.C. 1337(d)(1), (f)(1), (g)(1);
(3) For the purpose of the
investigation so instituted, the following
are hereby named as parties upon which
this notice of investigation shall be
served:
(a) The complainant is: Bracco
Diagnostics Inc., 259 Prospect Plains
Road, Building H, Monroe Township, NJ
08831.
(b) The respondents are the following
entities alleged to be in violation of
E:\FR\FM\01MYN1.SGM
01MYN1
Federal Register / Vol. 83, No. 84 / Tuesday, May 1, 2018 / Notices
section 337, and are the parties upon
which the complaint is to be served:
amozie on DSK30RV082PROD with NOTICES
(c) The Office of Unfair Import
Investigations, U.S. International Trade
Commission, 500 E Street SW, Suite
401, Washington, DC 20436; and
(4) For the investigation so instituted,
the Chief Administrative Law Judge,
U.S. International Trade Commission,
shall designate the presiding
Administrative Law Judge.
Responses to the complaint and the
notice of investigation must be
submitted by the named respondents in
accordance with section 210.13 of the
Commission’s Rules of Practice and
Procedure, 19 CFR 210.13. Pursuant to
19 CFR 201.16(e) and 210.13(a), such
responses will be considered by the
Commission if received not later than 20
days after the date of service by the
Commission of the complaint and the
notice of investigation. Extensions of
time for submitting responses to the
complaint and the notice of
investigation will not be granted unless
good cause therefor is shown.
Failure of a respondent to file a timely
response to each allegation in the
complaint and in this notice may be
deemed to constitute a waiver of the
right to appear and contest the
allegations of the complaint and this
notice, and to authorize the
administrative law judge and the
Commission, without further notice to
the respondent, to find the facts to be as
alleged in the complaint and this notice
and to enter an initial determination
and a final determination containing
such findings, and may result in the
issuance of an exclusion order or a cease
and desist order or both directed against
the respondent.
By order of the Commission.
Issued: April 25, 2018.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2018–09068 Filed 4–30–18; 8:45 am]
BILLING CODE 7020–02–P
VerDate Sep<11>2014
18:12 Apr 30, 2018
Jkt 244001
AGENCY:
particularly with respect to the
estimated public burden or associated
response time, have suggestions, need a
copy of the proposed information
collection instrument with instructions,
or desire any other additional
information, please contact Nicole
Timmons either by mail at CG–3, 10th
Floor, Washington, DC 20530–0001, by
email at Nicole.Timmons@usdoj.gov, or
by telephone at 202–236–2646. Written
comments and/or suggestions can also
be directed to the Office of Management
and Budget, Office of Information and
Regulatory Affairs, Attention
Department of Justice Desk Officer,
Washington, DC 20503 or sent to OIRA_
submissions@omb.eop.gov.
SUPPLEMENTARY INFORMATION: Written
comments and suggestions from the
public and affected agencies concerning
the proposed collection of information
are encouraged. Your comments should
address one or more of the following
four points:
—Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
—Evaluate the accuracy of the agency’s
estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
—Evaluate whether and if so how the
quality, utility, and clarity of the
information to be collected can be
enhanced; and
—Minimize the burden of the collection
of information on those who are to
respond, including through the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms
of information technology, e.g.,
permitting electronic submission of
responses.
The Department of Justice
(DOJ), U.S. Marshals Service (USMS),
will submit the following information
collection request to the Office of
Management and Budget (OMB) for
review and approval in accordance with
the Paperwork Reduction Act of 1995.
The proposed information collection
was previously published in the Federal
Register on January 17, 2018, allowing
for a 60-day comment period.
DATES: Comments are encouraged and
will be accepted for an additional 30
days until May 31, 2018.
FOR FURTHER INFORMATION CONTACT: If
you have additional comments,
Overview of This Information
Collection
(1) Type of Information Collection:
New collection.
(2) The Title of the Form/Collection:
Form CSO–005, Preliminary
Background Check Form.
(3) The agency form number, if any,
and the applicable component of the
Department sponsoring the collection:
Form number: CSO–005.
Component: U.S. Marshals Service,
U.S. Department of Justice.
(4) Affected public who will be asked
or required to respond, as well as a brief
abstract:
Primary: Court Security Officers/
Special Security Officer (CSO/SSO)
Applicants.
DEPARTMENT OF JUSTICE
Jubilant DraxImage Inc., 16751
TransCanada Highway, Kirkland,
´
Quebec, Canada, H9H 4J4
Jubilant Pharma Limited, 6 Temasek
Boulevard, #20–06 Suntec City,
Tower Four, Singapore 038986
Jubilant Life Sciences, Plot 1–A Sector
16–A Institutional Area, Noida, Uttar
Pradesh, 201301 India
19113
Foreign Claims Settlement
Commission
[F.C.S.C. Meeting and Hearing Notice No.
5–18]
Sunshine Act Meeting
The Foreign Claims Settlement
Commission, pursuant to its regulations
(45 CFR part 503.25) and the
Government in the Sunshine Act (5
U.S.C. 552b), hereby gives notice in
regard to the scheduling of open
meetings as follows:
Thursday, May 10, 2018: 10:00 a.m.—
Issuance of Proposed Decisions in
claims against Iraq.
Status: Open.
All meetings are held at the Foreign
Claims Settlement Commission, 601 D
Street NW, Suite 10300, Washington,
DC. Requests for information, or
advance notices of intention to observe
an open meeting, may be directed to:
Patricia M. Hall, Foreign Claims
Settlement Commission, 601 D Street
NW, Suite 10300, Washington, DC
20579. Telephone: (202) 616–6975.
Brian M. Simkin,
Chief Counsel.
[FR Doc. 2018–09098 Filed 4–26–18; 11:15 am]
BILLING CODE 4410–BA–P
DEPARTMENT OF JUSTICE
U.S. Marshals Service
[OMB Number 1105—NEW]
Agency Information Collection
Activities; Proposed eCollection
eComments Requested; Proposed
Collection; Comments Requested:
Form CSO–005, Preliminary
Background Check Form
U.S. Marshals Service,
Department of Justice.
ACTION: 30-Day notice.
SUMMARY:
PO 00000
Frm 00075
Fmt 4703
Sfmt 4703
E:\FR\FM\01MYN1.SGM
01MYN1
]]>Agencies
[Federal Register Volume 83, Number 84 (Tuesday, May 1, 2018)]
[Notices]
[Pages 19112-19113]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-09068]
-----------------------------------------------------------------------
INTERNATIONAL TRADE COMMISSION
[Investigation No. 337-TA-1110]
Certain Strontium-Rubidium Radioisotope Infusion Systems, and
Components Thereof Including Generators; Institution of Investigation
AGENCY: U.S. International Trade Commission
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that a complaint was filed with the
U.S. International Trade Commission on March 27, 2018, under section
337 of the Tariff Act of 1930, as amended, on behalf of Bracco
Diagnostics Inc. of Monroe Township, New Jersey. An amended complaint
was filed on April 13, 2018. The amended complaint alleges violations
of section 337 based upon the importation into the United States, the
sale for importation, and the sale within the United States after
importation of certain strontium-rubidium radioisotope infusion
systems, and components thereof including generators by reason of
infringement of U.S. Patent No. 9,814,826 (``the '826 patent''); U.S.
Patent No. 9,750,869 (``the '869 patent''); and U.S. Patent No.
9,750,870 (``the '870 patent''). The amended complaint further alleges
that an industry in the United States exists as required by the
applicable Federal Statute.
The complainant requests that the Commission institute an
investigation and, after the investigation, issue a limited exclusion
order and cease and desist orders.
ADDRESSES: The complaint, except for any confidential information
contained therein, is available for inspection during official business
hours (8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S.
International Trade Commission, 500 E Street SW, Room 112, Washington,
DC 20436, telephone (202) 205-2000. Hearing impaired individuals are
advised that information on this matter can be obtained by contacting
the Commission's TDD terminal on (202) 205-1810. Persons with mobility
impairments who will need special assistance in gaining access to the
Commission should contact the Office of the Secretary at (202) 205-
2000. General information concerning the Commission may also be
obtained by accessing its internet server at https://www.usitc.gov. The
public record for this investigation may be viewed on the Commission's
electronic docket (EDIS) at https://edis.usitc.gov.
FOR FURTHER INFORMATION CONTACT: Pathenia M. Proctor, The Office of
Unfair Import Investigations, U.S. International Trade Commission,
telephone (202) 205-2560.
SUPPLEMENTARY INFORMATION:
Authority: The authority for institution of this investigation
is contained in section 337 of the Tariff Act of 1930, as amended,
19 U.S.C. 1337 and in section 210.10 of the Commission's Rules of
Practice and Procedure, 19 CFR 210.10 (2018).
Scope of Investigation: Having considered the complaint, the U.S.
International Trade Commission, on April 24, 2018, ordered that--
(1) Pursuant to subsection (b) of section 337 of the Tariff Act of
1930, as amended, an investigation be instituted to determine whether
there is a violation of subsection (a)(1)(B) of section 337 in the
importation into the United States, the sale for importation, or the
sale within the United States after importation of certain strontium-
rubidium radioisotope infusion systems, and components thereof
including generators by reason of infringement of one or more of claims
1-3, 5, 9-14, 17-19, 26, and 28 of the '826 patent; claims 1-5, 8, 14,
24, and 27-30 of the '869 patent; and claims 1, 2, 8-13, 16, 17, 22,
and 27 of the '870 patent; and whether an industry in the United States
exists, or is in the process of being established, as required by
subsection (a)(2) of section 337;
(2) Pursuant to Commission Rule 210.50(b)(1), 19 CFR 210.50(b)(1),
the presiding administrative law judge shall take evidence or other
information and hear arguments from the parties and other interested
persons with respect to the public interest in this investigation, as
appropriate, and provide the Commission with findings of fact and a
recommended determination on this issue, which shall be limited to the
statutory public interest factors set forth in 19 U.S.C. 1337(d)(1),
(f)(1), (g)(1);
(3) For the purpose of the investigation so instituted, the
following are hereby named as parties upon which this notice of
investigation shall be served:
(a) The complainant is: Bracco Diagnostics Inc., 259 Prospect
Plains Road, Building H, Monroe Township, NJ 08831.
(b) The respondents are the following entities alleged to be in
violation of
[[Page 19113]]
section 337, and are the parties upon which the complaint is to be
served:
Jubilant DraxImage Inc., 16751 TransCanada Highway, Kirkland,
Qu[eacute]bec, Canada, H9H 4J4
Jubilant Pharma Limited, 6 Temasek Boulevard, #20-06 Suntec City, Tower
Four, Singapore 038986
Jubilant Life Sciences, Plot 1-A Sector 16-A Institutional Area, Noida,
Uttar Pradesh, 201301 India
(c) The Office of Unfair Import Investigations, U.S. International
Trade Commission, 500 E Street SW, Suite 401, Washington, DC 20436; and
(4) For the investigation so instituted, the Chief Administrative
Law Judge, U.S. International Trade Commission, shall designate the
presiding Administrative Law Judge.
Responses to the complaint and the notice of investigation must be
submitted by the named respondents in accordance with section 210.13 of
the Commission's Rules of Practice and Procedure, 19 CFR 210.13.
Pursuant to 19 CFR 201.16(e) and 210.13(a), such responses will be
considered by the Commission if received not later than 20 days after
the date of service by the Commission of the complaint and the notice
of investigation. Extensions of time for submitting responses to the
complaint and the notice of investigation will not be granted unless
good cause therefor is shown.
Failure of a respondent to file a timely response to each
allegation in the complaint and in this notice may be deemed to
constitute a waiver of the right to appear and contest the allegations
of the complaint and this notice, and to authorize the administrative
law judge and the Commission, without further notice to the respondent,
to find the facts to be as alleged in the complaint and this notice and
to enter an initial determination and a final determination containing
such findings, and may result in the issuance of an exclusion order or
a cease and desist order or both directed against the respondent.
By order of the Commission.
Issued: April 25, 2018.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2018-09068 Filed 4-30-18; 8:45 am]
BILLING CODE 7020-02-P
